Purpose: According to statistical data for 2022, thyroid cancer (TC) is in 3rd place in terms of detection frequency (9.4 %) in people under 30 years of age. At the same time, the frequency of malignant neoplasms (MNT) of the thyroid gland in young women from 0 to 29 years old is 13.6 %, which is more than the frequency of cervical cancer (8.4 %) [1]. According to the register of cancer patients of the Volga Federal District in 2022, the number of patients with cancer of the thyroid gland registered in oncology institutions with a diagnosis of cancer for the first time in their life is 2,231 people. By the end of this year, 20,908 patients had been registered for 5 years or more; mortality averaged 0.5 %. The above circumstances dictate the need to find ways to improve the results of radioiodine therapy for thyroid cancer based on its timely diagnosis, prevention of secondary resistance and optimization of treatment tactics. This became the prerequisites for the development of a modern tool for epidemiological analysis of the results of the use of radionuclide therapy 131I in the treatment of thyroid cancer in the FMBA system of Russia and the implementation of applied research wo
📖 افتح في inklap 🔗 DOI 📮 اطلب بحثاً